Warren Botnick, MD
Pulmonary Disease · Natchitoches, LANPI 1750382339
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $155,933 of the $213,216 with a category attached, or 73.1%. GSK accounts for 64.1% of it on its own, with 26 other manufacturers making up the rest. Among pulmonary disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 610 payments — averaging $349.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$137K
- Mylan Specialty L.p.$42K
- Viatris Specialty LLC$25K
- Sanofi$2K
- AstraZeneca$2K
- Jazz Pharmaceuticals Inc.$1K
- plus $5K from 21 others
Across 11 payments — averaging $1200.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$13K
What the payments were for
- Consulting fees$17,6358%
- Speaking & faculty fees$155,93373%
- Travel & lodging$27,53013%
- Food & beverage$11,9396%
- Education$1630%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 235 | $136,622 |
| Mylan Specialty L.p. | 78 | $41,987 |
| Viatris Specialty LLC | 24 | $24,745 |
| Sanofi | 13 | $1,767 |
| AstraZeneca | 84 | $1,726 |
| Jazz Pharmaceuticals Inc. | 4 | $1,103 |
| Hill-rom Company, Inc | 1 | $875 |
| Amgen | 4 | $601 |
| Viiv Healthcare Company | 1 | $600 |
| Baxter Healthcare | 32 | $517 |
| Regeneron Healthcare Solutions, Inc. | 22 | $501 |
| Boehringer Ingelheim | 32 | $492 |
| Bayer | 14 | $439 |
| Advanced Respiratory, Inc | 15 | $283 |
| Insmed, Inc. | 7 | $219 |
| Genentech USA, Inc. | 9 | $174 |
| Grifols USA, LLC | 7 | $124 |
| Electromed, Inc. | 6 | $91 |
| Sunovion Pharmaceuticals Inc. | 8 | $90 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Philips North America LLC | 2 | $49 |
| Gilead | 3 | $46 |
| Merck | 2 | $41 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Itamar Medical Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$65,081
- TRELEGY ELLIPTA$41,185
- AREXVY$38,314
- NUCALA$10,926
- ANORO$9,679
- SUNOSI$1,050
- The Monarch Airway Clearance System$875
- The Vest System 205 Acute Care$875
- The Vest System Model 105 Home Care$875
- TEZSPIRE$227
- FASENRA$224
- Adempas$200
- ANORO ELLIPTA$112
- Arikayce$100
How this compares
$213,216 in reported general payments places this provider in the 95th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 367 | $269,489 |
| Fasenra PenBenralizumab | 28 | $159,425 |
| NucalaMepolizumab | 38 | $144,827 |
| Pirfenidone | 20 | $65,031 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 58 | $41,485 |
| Advair HfaFluticasone Propion/Salmeterol | 92 | $33,748 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $28,861 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $23,342 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $12,571 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $10,950 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,717 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $5,439 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 202 | $5,203 |
| Roflumilast | 33 | $3,866 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta | $136,622 | $466,520498 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,726 | $46,92480 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat | $492 | $23,52242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Natchitoches
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Nicole LapinelNew Orleans$140K
- Courtney ShappleyNew Orleans$66K
- Charles GbadouweyMonroe$36K
- Susan GunnNew Orleans$28K
- Rachele GibsonCovington$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.